Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis.
Susceptibility of three different strains of Mycobacterium avium complex (MAC), i.e., one strain of M. avium (Mino) and two strains of M. intracellulare (31F093T and KUMS 9007), to nitric oxide (NO) generated by rat alveolar macrophages (M phi) or NO generated chemically by acidification of NO2- was examined in vitro. We also investigated the effects of NO on phagocytosis and superoxide anion (O2-) generation by M phi. The intracellular growth of M. avium Mino was significantly suppressed by NO generated by gamma interferon (IFN-gamma)-stimulated M phi, whereas that of two strains of M. intracellulare (31F093T and KUMS 9007) was not. M. avium Mino was also more susceptible to NO generated chemically by acidification of NO2- than the two M. intracellulare strains. In L-arginine (1 mM)-containing medium, NO release from the M phi assessed by measuring NO2- increased as the concentration of IFN-gamma increased. The enhancing potential of IFN-gamma for NO release became more pronounced when M phi were infected with 31F093T, an NO-resistant strain. A large amount of NO generated by IFN-gamma-stimulated M phi suppressed both phagocytosis and O2- generation by the M phi, especially after infection of the M phi with strain 31F093T. These results indicate that the intracellular growth of MAC is not always inhibited by NO generated by immunologically activated M phi; rather, NO generation induced by infection with an NO-resistant MAC strain suppresses phagocytosis of the M phi, which may allow extracellular spreading of such NO-resistant mycobacteria. Therefore, the pathogenic potential of MAC may be partly attributed to its resistance to NO.
Department of Microbiology, Kumamoto University School of Medicine, Japan.
T
T
Doi
M
M
Ando
T
T
Akaike
M
M
Suga
K
K
Sato
H
H
Maeda
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D006863:Hydrogen-Ion Concentration; D007111:Immunity, Cellular; D007371:Interferon-gamma / Q000494:pharmacology; D008262:Macrophage Activation; D016676:Macrophages, Alveolar / Q000276:immunology / Q000382:microbiology*; D008297:Male; D009162:Mycobacterium avium / Q000187:drug effects* / Q000472:pathogenicity; D009569:Nitric Oxide / Q000494:pharmacology*; D009573:Nitrites / Q000494:pharmacology; D010587:Phagocytosis / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D017208:Rats, Wistar; D011994:Recombinant Proteins; D016897:Respiratory Burst / Q000187:drug effects; D013481:Superoxides / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014376:Tuberculosis / Q000276:immunology*; D019323:omega-N-Methylarginine
D009573:Nitrites; D011994:Recombinant Proteins; D013481:Superoxides; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D007371:Interferon-gamma; D001120:Arginine; D013755:Tetradecanoylphorbol Acetate